Drug Profile
Lomvastomig - Roche
Alternative Names: anti-PD-1/TIM-3 bispecific antibody - Roche; Lomvastomig; PD1-TIM3 BsAb; RG-7769; RO-7121661Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Oesophageal cancer
- No development reported Malignant melanoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 26 Apr 2022 Discontinued - Phase-II for Solid tumours (IV) as of April 2022 (Roche pipelline, April 2022)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Locally recurrent, Second-line therapy or greater) in Denmark (IV)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Locally recurrent, Second-line therapy or greater) in Spain (IV)